Contains Nonbinding Recommendations

Draft Guidance on Methoxsalen

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

Active Ingredient: Methoxsalen

Dosage Form; Route: Capsules; oral

Recommended Studies: Two studies

1. Type of study: Fasting
   Design: Single-dose, two-way crossover in-vivo
   Strength: 10 mg
   Subjects: Healthy males and non-pregnant, non-lactating females, general population
   Additional Comments:
   - It is permissible to administer more than one capsule for the study to obtain adequate plasma concentration of the analyte to be measured.
   - Please exclude subjects who receive concomitant therapy (topically or systemically) with known photosensitizing agents.
   - Please do not allow subjects to be in sunlight (direct or indirect, even through window glass or cloud cover) for 8 hours post dose and subjects should be required to wear UVA-absorbing, wrap-around sunglasses during the daylight hours for the 24-hour period post dose. Participants should appropriately be advised of these restrictions in the informed consent.
   - Applicants may consider using a reference-scaled average bioequivalence approach for this highly variable drug substance/product. Provide evidence, from within the study, of high variability in the bioequivalence parameters, AUC and/or Cmax (i.e., within-subject variability ≥ 30%) when using this approach.

2. Type of study: Fed
   Design: Single-dose, two-way crossover in-vivo
   Strength: 10 mg
   Subjects: Healthy males and non-pregnant, non-lactating females, general population
   Additional Comments: Please see additional comments above.

Analytes to measure (in appropriate biological fluid): Methoxsalen in plasma

Bioequivalence based on (90% CI): Methoxsalen

Waiver request of in-vivo testing: Not Applicable

Recommended April 2010; Revised Jul 2017
**Dissolution test method and sampling times:** The dissolution information for this drug product can be found on the FDA-Recommended Dissolution Methods website, available to the public at the following location: [http://www.accessdata.fda.gov/scripts/cder/dissolution/](http://www.accessdata.fda.gov/scripts/cder/dissolution/). Conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the abbreviated new drug application (ANDA).